Effective antihypertensive strategies for high-risk patients with diabetic nephropathy

Journal of Investigative Medicine

Volumn 58, Issue 8, 2010, Pages 950-956

  Van Buren, Peter Noel ^a   Adams Huet, Beverley ^b   Toto, Robert Daniel ^a,b  

^a Division of Nephrology   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Albuminuria; Angiotensin converting enzyme inhibitor; Diabetes; Hypertension; Nephropathy

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOOP DIURETIC AGENT; POTASSIUM; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME VARIABLE; POTASSIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED;

EID: 78651474614     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181ff46a5     Document Type: Article

References (32)

1. Tuttle K. Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49: S12-S154.
2. U. S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008.
3. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
5. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;1:1175-1179.
6. Parving HH, Andersen AR, Smidt UM, et al. Diabetic nephropathy and arterial hypertension. The effect of antihypertensive treatment. Diabetes. 1983;32(suppl 2):83-87.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
8. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
9. Parving HH, Hommel E, Jensen BR, et al. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 2001;60:228-234.
10. Parving HH, Andersen S, Jacobsen P, et al. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Semin Nephrol. 2004;24:147-157.
11. Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163:1555-1565.
12. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-2320. (Pubitemid 38670018)
13. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43: S1-S290.
14. Toto RD. Treatment of hypertension in chronic kidney disease. Semin Nephrol. 2005;25:435-439.
15. Berl T, Hunsicker L, Lewis J, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170-2179.
16. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
17. Mehdi U, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or a mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641-2650.
18. Wright JT Jr, Kusek JW, Toto RD, et al. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17:3SY16S.
19. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317:703-713.
20. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335-342.
21. Joss N, Ferguson C, Brown C, et al. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM. 2004;97:219-227.
22. Barnett A, Bain S, Bouter P, et al. Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine. 2004;351:1952-1962.
23. Rossing K, Schjoedt K, Jensen B, et al. Enhanced renoprotective effect of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190-1198.
24. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540-1546.
25. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(supp 1): S1-S290.
26. Verhave JC, Hillege HL, Burgerhof JG, et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med. 2004;256:324-330.
27. Heeg JE. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36:272-279.
28. Krolewski A. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 2005;332:1251-1255.
29. U. S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD; 2009.
30. Gansevoort RT. Evaluation of measures of urinary albumin excretion. Am J Epidemiol. 2006;164:725-727.
31. Schjoedt K, Rossing K, Juhl T, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829-2836.
32. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial Impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536-542.